Weight-Loss drug may boost IVF success for overweight women

NCT ID NCT07242534

Recruiting now Symptom relief Sponsor: Fundacion Dexeus Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether taking semaglutide (a weight-loss medication) for 12 weeks before starting IVF can lead to better-quality embryos in overweight or obese women. About 62 women aged 38 or younger with a BMI between 27 and 40 will be randomly assigned to receive semaglutide or no pre-treatment. The goal is to see if the drug improves the number of good-quality blastocysts available for freezing.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INFERTILITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

infertility disorder Obesity obesity disorder Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

INFERTILITY OBESITY

Contacts and locations

Locations

Departamento de Ginecología Obstetricia y Reproducción. Hospital Universitari Dexeus
RECRUITING

Barcelona, 08028, Spain
Dexeus Mujer Reus
NOT_YET_RECRUITING

Reus, Tarragona, 43202, Spain
Dexeus Mujer Sabadell
NOT_YET_RECRUITING

Sabadell, Barcelona, Spain
Dexeus Mujer Sant Cugat
NOT_YET_RECRUITING

Sant Cugat del Vallès, Barcelona, 08195, Spain
Dexeus Mujer Tarragona
NOT_YET_RECRUITING

Tarragona, 43206, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.